logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Approves Abbott's FreeStyle InsuLinx Blood Glucose Monitoring System

Abbott Laboratories (ABT) announced that it has received U.S. Food and Drug Administration clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System.
The company said that the system included a touch-screen interface, automated logbook. The system also offers Personalization features, including the ability to upload weekly messages, pre-and post-meal markers and a personal photograph to the home screen.

This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers.

The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months, the company said.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing.... Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations.
comments powered by Disqus
Follow RTT